In the phase III IMpassion130 trial, atezolizumab with nab-paclitaxel in first line for aTNBC showed a statistically significant progression-free survival (PFS) benefit over nab-paclitaxel regardless of PD-L1 status, and a numerically longer overall survival (OS) in the PD-L1 positive tumor subgroup population5–7. Here, CD274 is linked to neoplasm.